A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial

Background: Though denosumab is an effective treatment for osteoporosis, the rebound effect after discontinuation has drawn investigators' attention. It includes a dramatic loss of gained bone mineral density (BMD) and an increased risk of vertebral fractures. This prospective multi-institution...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chia-Che, Wang, Chen-Yu, Hung, Chih-Chien, Huang, Chuan-Ching, Li, Chung-Yi, Chen, Hsuan-Yu, Chang, Yun-Liang, Tseng, Wo-Jan, Wang, Ting-Ming, Yang, Rong-Sen, Wong, Tze-Hong, Fu, Shau-Huai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455904/
https://www.ncbi.nlm.nih.gov/pubmed/34568375
http://dx.doi.org/10.3389/fmed.2021.717168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455904/
https://www.ncbi.nlm.nih.gov/pubmed/34568375
http://dx.doi.org/10.3389/fmed.2021.717168

Ejemplares similares